Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 61 to 69 of 69 entries
Sorted by: Best Match Show Resources per page
Functional metal-organic frameworks via ligand doping: influences of ligand charge and steric demand.

Inorganic chemistry

Wang C, Liu D, Xie Z, Lin W.
PMID: 24422471
Inorg Chem. 2014 Feb 03;53(3):1331-8. doi: 10.1021/ic402015q. Epub 2014 Jan 14.

Doping a functional ligand into a known crystalline system built from ligands of similar shape and length provides a powerful strategy to construct functional metal-organic frameworks (MOFs) with desired functionality and structural topology. This mix-and-match approach mimics the widely...

Cite
Wang C, Liu D, Xie Z, et al. Functional metal-organic frameworks via ligand doping: influences of ligand charge and steric demand. Inorg Chem. 2014;53(3):1331-8doi: 10.1021/ic402015q.
Wang, C., Liu, D., Xie, Z., & Lin, W. (2014). Functional metal-organic frameworks via ligand doping: influences of ligand charge and steric demand. Inorganic chemistry, 53(3), 1331-8. https://doi.org/10.1021/ic402015q
Wang, Cheng, et al. "Functional metal-organic frameworks via ligand doping: influences of ligand charge and steric demand." Inorganic chemistry vol. 53,3 (2014): 1331-8. doi: https://doi.org/10.1021/ic402015q
Wang C, Liu D, Xie Z, Lin W. Functional metal-organic frameworks via ligand doping: influences of ligand charge and steric demand. Inorg Chem. 2014 Feb 03;53(3):1331-8. doi: 10.1021/ic402015q. Epub 2014 Jan 14. PMID: 24422471.
Copy Download .nbib Format: NLM
Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes.

The Journal of pharmacology and experimental therapeutics

Pognan F, Couttet P, Demin I, Jaitner B, Pang Y, Roubenoff R, Sutter E, Timsit Y, Valentin MA, Vogel B, Woerly G, Wolf A, Schramm U.
PMID: 30894455
J Pharmacol Exp Ther. 2019 Jun;369(3):428-442. doi: 10.1124/jpet.118.254128. Epub 2019 Mar 20.

The colony-stimulating factor-1 (CSF-1) receptor pathway has been implicated in a variety of diseases, and CSF-1-dependent mechanisms are also involved in bloodborne protein clearance. Lacnotuzumab is a novel, high-affinity, humanized, anti-CSF-1 monoclonal antibody that prevents CSF-1-mediated receptor activation. This...

Cite
Pognan F, Couttet P, Demin I, et al. Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes. J Pharmacol Exp Ther. 2019;369(3):428-442doi: 10.1124/jpet.118.254128.
Pognan, F., Couttet, P., Demin, I., Jaitner, B., Pang, Y., Roubenoff, R., Sutter, E., Timsit, Y., Valentin, M. A., Vogel, B., Woerly, G., Wolf, A., & Schramm, U. (2019). Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes. The Journal of pharmacology and experimental therapeutics, 369(3), 428-442. https://doi.org/10.1124/jpet.118.254128
Pognan, Francois, et al. "Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes." The Journal of pharmacology and experimental therapeutics vol. 369,3 (2019): 428-442. doi: https://doi.org/10.1124/jpet.118.254128
Pognan F, Couttet P, Demin I, Jaitner B, Pang Y, Roubenoff R, Sutter E, Timsit Y, Valentin MA, Vogel B, Woerly G, Wolf A, Schramm U. Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes. J Pharmacol Exp Ther. 2019 Jun;369(3):428-442. doi: 10.1124/jpet.118.254128. Epub 2019 Mar 20. PMID: 30894455.
Copy Download .nbib Format: NLM
Reactive Pulsed Laser Deposition of Clustered-Type MoS.

Nanomaterials (Basel, Switzerland)

Fominski V, Demin M, Nevolin V, Fominski D, Romanov R, Gritskevich M, Smirnov N.
PMID: 32244608
Nanomaterials (Basel). 2020 Apr 01;10(4). doi: 10.3390/nano10040653.

We studied the tribological properties of amorphous molybdenum sulfide (MoS

Cite
Fominski V, Demin M, Nevolin V, et al. Reactive Pulsed Laser Deposition of Clustered-Type MoS. Nanomaterials (Basel). 2020;10(4)doi: 10.3390/nano10040653.
Fominski, V., Demin, M., Nevolin, V., Fominski, D., Romanov, R., Gritskevich, M., & Smirnov, N. (2020). Reactive Pulsed Laser Deposition of Clustered-Type MoS. Nanomaterials (Basel, Switzerland), 10(4), . https://doi.org/10.3390/nano10040653
Fominski, V, et al. "Reactive Pulsed Laser Deposition of Clustered-Type MoS." Nanomaterials (Basel, Switzerland) vol. 10,4 (2020). doi: https://doi.org/10.3390/nano10040653
Fominski V, Demin M, Nevolin V, Fominski D, Romanov R, Gritskevich M, Smirnov N. Reactive Pulsed Laser Deposition of Clustered-Type MoS. Nanomaterials (Basel). 2020 Apr 01;10(4). doi: 10.3390/nano10040653. PMID: 32244608; PMCID: PMC7221609.
Copy Download .nbib Format: NLM
PARK2 Suppresses Proliferation and Tumorigenicity in Non-small Cell Lung Cancer.

Frontiers in oncology

Duan H, Lei Z, Xu F, Pan T, Lu D, Ding P, Zhu C, Pan C, Zhang S.
PMID: 31508359
Front Oncol. 2019 Aug 23;9:790. doi: 10.3389/fonc.2019.00790. eCollection 2019.

No abstract available.

Cite
Duan H, Lei Z, Xu F, et al. PARK2 Suppresses Proliferation and Tumorigenicity in Non-small Cell Lung Cancer. Front Oncol. 2019;9:790doi: 10.3389/fonc.2019.00790.
Duan, H., Lei, Z., Xu, F., Pan, T., Lu, D., Ding, P., Zhu, C., Pan, C., & Zhang, S. (2019). PARK2 Suppresses Proliferation and Tumorigenicity in Non-small Cell Lung Cancer. Frontiers in oncology, 9790. https://doi.org/10.3389/fonc.2019.00790
Duan, Huijie, et al. "PARK2 Suppresses Proliferation and Tumorigenicity in Non-small Cell Lung Cancer." Frontiers in oncology vol. 9 (2019): 790. doi: https://doi.org/10.3389/fonc.2019.00790
Duan H, Lei Z, Xu F, Pan T, Lu D, Ding P, Zhu C, Pan C, Zhang S. PARK2 Suppresses Proliferation and Tumorigenicity in Non-small Cell Lung Cancer. Front Oncol. 2019 Aug 23;9:790. doi: 10.3389/fonc.2019.00790. eCollection 2019. PMID: 31508359; PMCID: PMC6716169.
Copy Download .nbib Format: NLM
Variation in tumor pH affects pH-triggered delivery of peptide-modified magnetic nanoparticles.

Nanomedicine : nanotechnology, biology, and medicine

Pershina AG, Brikunova OY, Demin AM, Abakumov MA, Vaneev AN, Naumenko VA, Erofeev AS, Gorelkin PV, Nizamov TR, Muslimov AR, Timin AS, Malkeyeva D, Kiseleva E, Vtorushin SV, Larionova IV, Gereng EA, Minin AS, Murzakaev AM, Krasnov VP, Majouga AG, Ogorodova LM.
PMID: 33096245
Nanomedicine. 2021 Feb;32:102317. doi: 10.1016/j.nano.2020.102317. Epub 2020 Oct 21.

Acidification of the extracellular matrix, an intrinsic characteristic of many solid tumors, is widely exploited for physiologically triggered delivery of contrast agents, drugs, and nanoparticles to tumor. However, pH of tumor microenvironment shows intra- and inter-tumor variation. Herein, we...

Cite
Pershina AG, Brikunova OY, Demin AM, et al. Variation in tumor pH affects pH-triggered delivery of peptide-modified magnetic nanoparticles. Nanomedicine. 2020;32:102317doi: 10.1016/j.nano.2020.102317.
Pershina, A. G., Brikunova, O. Y., Demin, A. M., Abakumov, M. A., Vaneev, A. N., Naumenko, V. A., Erofeev, A. S., Gorelkin, P. V., Nizamov, T. R., Muslimov, A. R., Timin, A. S., Malkeyeva, D., Kiseleva, E., Vtorushin, S. V., Larionova, I. V., Gereng, E. A., Minin, A. S., Murzakaev, A. M., Krasnov, V. P., Majouga, A. G., & Ogorodova, L. M. (2021). Variation in tumor pH affects pH-triggered delivery of peptide-modified magnetic nanoparticles. Nanomedicine : nanotechnology, biology, and medicine, 32102317. https://doi.org/10.1016/j.nano.2020.102317
Pershina, Alexandra G, et al. "Variation in tumor pH affects pH-triggered delivery of peptide-modified magnetic nanoparticles." Nanomedicine : nanotechnology, biology, and medicine vol. 32 (2021): 102317. doi: https://doi.org/10.1016/j.nano.2020.102317
Pershina AG, Brikunova OY, Demin AM, Abakumov MA, Vaneev AN, Naumenko VA, Erofeev AS, Gorelkin PV, Nizamov TR, Muslimov AR, Timin AS, Malkeyeva D, Kiseleva E, Vtorushin SV, Larionova IV, Gereng EA, Minin AS, Murzakaev AM, Krasnov VP, Majouga AG, Ogorodova LM. Variation in tumor pH affects pH-triggered delivery of peptide-modified magnetic nanoparticles. Nanomedicine. 2021 Feb;32:102317. doi: 10.1016/j.nano.2020.102317. Epub 2020 Oct 21. PMID: 33096245.
Copy Download .nbib Format: NLM
Irisin rescues diabetic cardiac microvascular injury via ERK1/2/Nrf2/HO-1 mediated inhibition of oxidative stress.

Diabetes research and clinical practice

Zhu D, Zhang X, Wang F, Ye Q, Yang C, Liu D.
PMID: 34863716
Diabetes Res Clin Pract. 2021 Dec 02;183:109170. doi: 10.1016/j.diabres.2021.109170. Epub 2021 Dec 02.

AIMS: Cardiac microvascular dysfunction is a common feature across cardiovascular complications in diabetes, while effective therapy remains elusive. This study was designed to evaluate the effect of irisin on cardiac microvascular injury in type 2 diabetes mellitus (T2DM).METHODS: T2DM...

Cite
Zhu D, Zhang X, Wang F, et al. Irisin rescues diabetic cardiac microvascular injury via ERK1/2/Nrf2/HO-1 mediated inhibition of oxidative stress. Diabetes Res Clin Pract. 2021;183:109170doi: 10.1016/j.diabres.2021.109170.
Zhu, D., Zhang, X., Wang, F., Ye, Q., Yang, C., & Liu, D. (2021). Irisin rescues diabetic cardiac microvascular injury via ERK1/2/Nrf2/HO-1 mediated inhibition of oxidative stress. Diabetes research and clinical practice, 183109170. https://doi.org/10.1016/j.diabres.2021.109170
Zhu, Di, et al. "Irisin rescues diabetic cardiac microvascular injury via ERK1/2/Nrf2/HO-1 mediated inhibition of oxidative stress." Diabetes research and clinical practice vol. 183 (2021): 109170. doi: https://doi.org/10.1016/j.diabres.2021.109170
Zhu D, Zhang X, Wang F, Ye Q, Yang C, Liu D. Irisin rescues diabetic cardiac microvascular injury via ERK1/2/Nrf2/HO-1 mediated inhibition of oxidative stress. Diabetes Res Clin Pract. 2021 Dec 02;183:109170. doi: 10.1016/j.diabres.2021.109170. Epub 2021 Dec 02. PMID: 34863716.
Copy Download .nbib Format: NLM
Relationship among atrial fibrillation, the CHA.

BMC cardiovascular disorders

Shi B, Liu D, Wang Q, Geng X, Hou Q, Gu G, Xie R, Cui W.
PMID: 34600490
BMC Cardiovasc Disord. 2021 Oct 02;21(1):474. doi: 10.1186/s12872-021-02276-z.

BACKGROUND: Recent evidence has shown that the pathogenesis of ischaemic stroke associated with atrial fibrillation (AF) is complex and involves other factors in addition to arrhythmias. The purpose of this study was to investigate the relationship among AF, CHAMETHODS:...

Cite
Shi B, Liu D, Wang Q, et al. Relationship among atrial fibrillation, the CHA. BMC Cardiovasc Disord. 2021;21(1):474doi: 10.1186/s12872-021-02276-z.
Shi, B., Liu, D., Wang, Q., Geng, X., Hou, Q., Gu, G., Xie, R., & Cui, W. (2021). Relationship among atrial fibrillation, the CHA. BMC cardiovascular disorders, 21(1), 474. https://doi.org/10.1186/s12872-021-02276-z
Shi, Boqun, et al. "Relationship among atrial fibrillation, the CHA." BMC cardiovascular disorders vol. 21,1 (2021): 474. doi: https://doi.org/10.1186/s12872-021-02276-z
Shi B, Liu D, Wang Q, Geng X, Hou Q, Gu G, Xie R, Cui W. Relationship among atrial fibrillation, the CHA. BMC Cardiovasc Disord. 2021 Oct 02;21(1):474. doi: 10.1186/s12872-021-02276-z. PMID: 34600490; PMCID: PMC8487546.
Copy Download .nbib Format: NLM
Efficacy of cipargamin (KAE609) in a randomized, Phase II dose-escalation study in adults in sub-Saharan Africa with uncomplicated Plasmodium falciparum malaria.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Schmitt EK, Ndayisaba G, Yeka A, Asante KP, Grobusch MP, Karita E, Mugerwa H, Asiimwe S, Oduro A, Fofana B, Doumbia S, Su G, Csermak Renner K, Venishetty VK, Sayyed S, Straimer J, Demin I, Barsainya S, Boulton C, Gandhi P.
PMID: 34410358
Clin Infect Dis. 2021 Aug 19; doi: 10.1093/cid/ciab716. Epub 2021 Aug 19.

BACKGROUND: Cipargamin (KAE609) is a potent antimalarial in Phase II. Here we report efficacy, pharmacokinetics, and resistance marker analysis across a range of cipargamin doses. These were secondary endpoints from a study primarily conducted to assess the hepatic safety...

Cite
Schmitt EK, Ndayisaba G, Yeka A, et al. Efficacy of cipargamin (KAE609) in a randomized, Phase II dose-escalation study in adults in sub-Saharan Africa with uncomplicated Plasmodium falciparum malaria. Clin Infect Dis. 2021;doi: 10.1093/cid/ciab716.
Schmitt, E. K., Ndayisaba, G., Yeka, A., Asante, K. P., Grobusch, M. P., Karita, E., Mugerwa, H., Asiimwe, S., Oduro, A., Fofana, B., Doumbia, S., Su, G., Csermak Renner, K., Venishetty, V. K., Sayyed, S., Straimer, J., Demin, I., Barsainya, S., Boulton, C., & Gandhi, P. (2021). Efficacy of cipargamin (KAE609) in a randomized, Phase II dose-escalation study in adults in sub-Saharan Africa with uncomplicated Plasmodium falciparum malaria. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, . https://doi.org/10.1093/cid/ciab716
Schmitt, Esther K, et al. "Efficacy of cipargamin (KAE609) in a randomized, Phase II dose-escalation study in adults in sub-Saharan Africa with uncomplicated Plasmodium falciparum malaria." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. (2021). doi: https://doi.org/10.1093/cid/ciab716
Schmitt EK, Ndayisaba G, Yeka A, Asante KP, Grobusch MP, Karita E, Mugerwa H, Asiimwe S, Oduro A, Fofana B, Doumbia S, Su G, Csermak Renner K, Venishetty VK, Sayyed S, Straimer J, Demin I, Barsainya S, Boulton C, Gandhi P. Efficacy of cipargamin (KAE609) in a randomized, Phase II dose-escalation study in adults in sub-Saharan Africa with uncomplicated Plasmodium falciparum malaria. Clin Infect Dis. 2021 Aug 19; doi: 10.1093/cid/ciab716. Epub 2021 Aug 19. PMID: 34410358.
Copy Download .nbib Format: NLM
No effect of sleeved arms on the accuracy of blood pressure measurement.

Internal medicine journal

Li Y, Li Y, Li F, Liu D, Zhang Y, Cui X, Cui W.
PMID: 32975880
Intern Med J. 2021 Dec;51(12):2087-2094. doi: 10.1111/imj.15071.

BACKGROUND: It is recommended that blood pressure should be measured on a bare upper arm with an appropriately sized cuff. However, in practice, it is more convenient to measure blood pressure on sleeved arms.AIMS: We aim to examine the...

Cite
Li Y, Li Y, Li F, et al. No effect of sleeved arms on the accuracy of blood pressure measurement. Intern Med J. 2021;51(12):2087-2094doi: 10.1111/imj.15071.
Li, Y., Li, Y., Li, F., Liu, D., Zhang, Y., Cui, X., & Cui, W. (2021). No effect of sleeved arms on the accuracy of blood pressure measurement. Internal medicine journal, 51(12), 2087-2094. https://doi.org/10.1111/imj.15071
Li, Ya, et al. "No effect of sleeved arms on the accuracy of blood pressure measurement." Internal medicine journal vol. 51,12 (2021): 2087-2094. doi: https://doi.org/10.1111/imj.15071
Li Y, Li Y, Li F, Liu D, Zhang Y, Cui X, Cui W. No effect of sleeved arms on the accuracy of blood pressure measurement. Intern Med J. 2021 Dec;51(12):2087-2094. doi: 10.1111/imj.15071. PMID: 32975880.
Copy Download .nbib Format: NLM
Showing 61 to 69 of 69 entries